Acrivon Therapeutics Inc
XNAS:ACRV
| Market Cap (Intraday) | 77.63M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.40 |
| 50-Day MA | $2.26 |
| 200-Day MA | $1.78 |
Acrivon Therapeutics Inc Stock, XNAS:ACRV
480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.207.8979
Number of Employees: 58
Description
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.